TP53 and acute myeloid leukemia: A 2024 study published in Frontiers in Pharmacology examined the metabolic and physiological hallmarks of TP53-mutated AML, highlighting an upregulated glycolysis pathway as a key driver of chemoresistance and immune evasion (104, 105).